Loading…
CRF Mediates Stress-Induced Pathophysiological High-Frequency Oscillations in Traumatic Brain Injury
It is not known why there is increased risk to have seizures with increased anxiety and stress after traumatic brain injury (TBI). Stressors cause the release of corticotropin-releasing factor (CRF) both from the hypothalamic pituitary adrenal (HPA) axis and from CNS neurons located in the central a...
Saved in:
Published in: | eNeuro 2019-03, Vol.6 (2), p.ENEURO.0334-18.2019 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | It is not known why there is increased risk to have seizures with increased anxiety and stress after traumatic brain injury (TBI). Stressors cause the release of corticotropin-releasing factor (CRF) both from the hypothalamic pituitary adrenal (HPA) axis and from CNS neurons located in the central amygdala and GABAergic interneurons. We have previously shown that CRF signaling is plastic, becoming excitatory instead of inhibitory after the kindling model of epilepsy. Here, using Sprague Dawley rats we have found that CRF signaling increased excitability after TBI. Following TBI, CRF type 1 receptor (CRFR
)-mediated activity caused abnormally large electrical responses in the amygdala, including fast ripples, which are considered to be epileptogenic. After TBI, we also found the ripple (120-250 Hz) and fast ripple activity (>250 Hz) was cross-frequency coupled with θ (3-8 Hz) oscillations. CRFR
antagonists reduced the incidence of phase coupling between ripples and fast ripples. Our observations indicate that pathophysiological signaling of the CRFR
increases the incidence of epileptiform activity after TBI. The use for CRFR
antagonist may be useful to reduce the severity and frequency of TBI associated epileptic seizures. |
---|---|
ISSN: | 2373-2822 2373-2822 |
DOI: | 10.1523/ENEURO.0334-18.2019 |